Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the
coverage of the most important and influential journals
to meet the needs of the global scientific community.
A bioequivalence and pharmacokinetics profiles of two doxycycline powder formulations
(Providox® and Doxyvet 0-50 S®) were compared
in 24 healthy chickens following administration of a single oral dose (20 mg/kg
bw). Serial blood samples were drawn at 10 points after administration to determine
doxycycline concentrations in chicken plasma by HPLC/UV. the pharmacokinetics
parameters; area under plasma concentration-time curve (AUC0-24),
maximum plasma concentration (Cmax) were determined for both formulations.
The average means of AUC0-24 and Cmax for
Providox® and Doxyvet 0-50 S® were very close
(62.32 ± 3.34 and 57.55 ± 4.66 µg.h/ml and 5.36 ±
0.26 and 5.08 ± 0.25 µg/ml, respectively) with no significant differences
based on ANOVA. The 90% confidence intervals of the parameters AUC0-24 and Cmax between two formulations were within the range
80 to 125 % of bioequivalence according to US FDA regulation. The relative bioavailability
of Providox® compared to Doxyvet 0-50 S® was 108.24%.
Therefore, the Providox® and Doxyvet 0 - 50 S®
were considered to be bioequivalent.
